BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

20 articles for Y Teffera

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
The Discovery and Hit-to-Lead Optimization of Tricyclic Sulfonamides as Potent and Efficacious Potentiators of Glycine Receptors.EBI
Amgen
Optimization of a Novel Quinazolinone-Based Series of Transient Receptor Potential A1 (TRPA1) Antagonists Demonstrating Potent in Vivo Activity.EBI
Amgen
Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.EBI
Amgen
Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme.EBI
Amgen
Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitors.EBI
Amgen
Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.EBI
Amgen
Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.EBI
Amgen
Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors.EBI
Amgen
The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.EBI
Amgen
Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.EBI
Amgen
Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.EBI
Amgen
Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.EBI
Amgen
Discovery of triazine-benzimidazoles as selective inhibitors of mTOR.EBI
Amgen
Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.EBI
Amgen
Discovery of novel 1,2,3,4-tetrahydroisoquinolines and 3,4-dihydroisoquinoline-1(2H)-ones as potent and selective inhibitors of KDR: synthesis, SAR, and pharmacokinetic properties.EBI
Amgen
Substituted piperazines as novel dipeptidyl peptidase IV inhibitors.EBI
Merck
Amidines as amide bond replacements in VLA-4 antagonists.EBI
Merck Research Laboratories
The discovery of acylated beta-amino acids as potent and orally bioavailable VLA-4 antagonists.EBI
Merck Research Laboratories
IAP antagonistsBDB
Bristol-Myers Squibb
Lysine sulfonamides as novel HIV-protease inhibitors: optimization of the Nepsilon-acyl-phenyl spacer.BDB
Pharmacor